Member Info for dactions

Goldust - very good observation - I for one hadn't spotted the possible Pzifer/Viagra link.

Great questions indeed - but I doubt there will be clear answers. For those invested at the beginning but buying after the IPO at 6p - 8p, I doubt there will be immediate fireworks on re-listing but if purchased nearer the suspension price of 4.3p then it should look good even though the AIM market has generally sunk in the meantime. The positive noises from Sound and Echo shareholders is as much because they have been properly treated/informed by their BODs. That hasn't been the case with SRON and I doubt we'll see another situation quite like this one coming to the market on one basis and changing within a few months into something else. Im my opinion this is now a play on the talents of Sara Edmonson, Chief Executive Officer and James Parsons, Non-Executive Chairman. We sit back and watch in hope.

Daily Mail had a spot on Falanx in its 'Stock Watch' spot this morning. QUOTE: Falanx shares flew as the AIM-listed cyber defence services provider announced two new contract wins, which should boost recurring revenue at the firm. It has won three-year contract worth �700,000 for security monitoring for an international law firm, and has expanded a three-year deal with another client, which will now be worth �380,000. Falanx's Midgard service identifies potential cyber attacks. Shares soared 16.8% or 0.68p, to 4.75p ENDQUOTE I'm not sure I'd agree with the adjective "flew" because anything looks good from a low base, but it's good to see some positive news to chew over rather than the very bearish & unsupported comments on some of the Share Boards these past few months.

Fallingknife - I don't get why you keep posting the same old theme re. Falanx - once or twice I accept but this constant repeat of the same message over and over - for what purpose if it's not deramping ?

Thanks Jupiter for the link - having now listened to Michael Hunt, frankly it's not hard to see why the share is where it is. I came away thinking all I'd heard was how to progress through an ever deepening swamp ! There's no energy in him anymore - and that's putting it kindly. Herein lies the reason why the sp is languishing - is the company itself languishing too ?

Here is the presentation by Sara Edmondson on Stef's youtube channel. I'm coming round to believing this Coro creation is a personal vehicle for Sarah and Parsons new ambitions. If you believe in them, then you keep your investment in SRON, sit back, wait and watch the fireworks happen and the SP rise as it did in Echo ! Or is that being too simplistic ? https://www.youtube.com/watch?v=Y2JJtHeEDqo&pbjreload=10

I don't think anyone outside the BOD, the Broker's, the Nomad, the corner stone Investor etc etc knows. That is - we the private investors DON'T

Can anyone explain please today's RNS whereby Spreadex increased their holding by a sizable amount and that it related in part to a CFD contract ? How should we view this holding ?

. . . today's RNS Appointing a new CFO with reponsibilities for the AIM market - hopefully, for a shareprice lift-off ?

Can't say that I understand all those massive transactions yesterday - were they Sells in fact ?

I'm finding it hard to be so positive as the rest of you - I am a shareholder although my average is closer to 5p rather than the 7p some of you are in. Remember it's less than a year when placing at 5p, followed by 4p just 4 months ago and almost immediately after that we were suspended. Doesn't the market deserve some better explanation as to what is going on here ? Less than a year ago, we were supposedly a monetised Italian Gas company and now where a global exploratory one - don't SRTON's PIs deserve some more explanation ? Why should these investors get additional warrants of 6.5p on a basis of 1 for subscribing to two shares at 4.38p. Where in this latest RNS is any talk about the mechanics of the open offer to PI's and why are PIs precluded from the warrants ? Why is it necessary to pay a 10% commission when no effort has been made to explain to current shareholders what's happening which might have allowed raising more capital at little or no fees.

When a document is that long and with all the "this company will still be owed this and that company will have a charge against that" I think we are being screwed big time ! The Directors with their easy options are not - that is the easiest paragraph to read ! To be suspended for over 6 months for what ? - beggars belief - so much for AIM protection, PO Valley are doing what they like and SRON has been picked out as the least vociferous shareholders in my opinion.

Last Friday (19th) there was an end-year update from the Woodford Patient Capital Trust on some of the stocks within that fund. Woodford holds a massive stake in RM2 and these were the comments that applied to RM2 - does it hold out hope for the coninuance of RM2 ? Having personally lost a small fortune (relative to my funds) on this miserable share, I wish I could interpret what it might mean for this company's future ? Quote: RM2 International The company announced in December that it had been unsuccessful in securing funding for the year ahead. RM2 has had its fair share of challenges in recent years and in many respects, it epitomises how difficult it can be for early-stage businesses to develop and scale-up. We continue to see value in the disruptive pallet technology that RM2 International has been progressing towards commercialisation, overcoming many production challenges and enhancing the product offering along the way. The position is now small in the context of the patient capital portfolio but we will continue to work with the company to find an appropriate solution for its capital requirements and to give it the best chance of fulfilling its potential.

Last Friday there was an update on the portfolio of Woodford Patient Capital Trust. Within that fund is a substantial holding of RENE. Here's the quote from that report: Quote: ReNeuron ReNeuron received regulatory approval to start a phase IIb clinical study in the US for its CTX cell therapy for patients suffering from stroke disability. This is a great example of the patience that is required to achieve successful outcomes in this area of investing � the CTX cell therapy technology has already been in its development phase for almost ten years. Although this particular study is expected to read out in late 2019 and further pivotal trials are likely to be required before the company can progress towards market approval, the commercial opportunity ahead for ReNeuron�s innovative pipeline of assets is, in our view, substantial. ReNeuron, thus far, is doing everything that we hoped it would in terms of operational development. The long-term potential here is undeniable but the short-term interest from the stock market remains almost imperceptible. In an increasingly short-term world, businesses like ReNeuron are exactly the sort of investment opportunity that the Patient Capital Trust was set-up to support, nurture and, ultimately, benefit from as they fulfil their commercial potential. As we have consistently said, not all will fulfil that potential, but the rewards for those that do succeed will be substantial. Endquote

So now we know - after hours - not one but 3 delayed sales, 2 of 1million shares which is bad enough but one of 10million shares traded at 12.30pm when the market was in an otherwise upward trend of good buying. All of those buyers, in any other business, could be justified in complaining of fraud - but in the stockmarket it is par for the course to make the rules suit the major players !

I agree Gibson - I added myself mid-afternoon (at 1.44) when the price was 1.40 - .1.45 and despite a preponderance of buys going through at a similar level for an hour, the Ask was dropped to 1.40. I can only assume there's a large as yet unrecorded Sell going through which may get reported later. Such are the shenaningons of the AIM market.

Right now RENE can be considered a "Cash Cow" in the sense that it has such massive cash reserves courtesy of the 5p placing with Neil Woodford et al. It may have poor PR management but it certainly has a good scientific one as far as I've been able to see these past years.

Visainn - I don't undestand the significance of today's RNS - can anyone fill me in please why we at Opti benefit ?

Ethical - seems you have quite a gripe against OBT ?

It's good to have a such an early and positive announcement of last year's business. I'm hopeful of steady growth in the SP but I'm more hopeful that they have another ace up their sleeve re. further accretive acquisition ? Quote: TP Group (AIM: TPG), the specialist services and engineering group, is pleased to report that the Group's trading for the year ended 31 December 2017 remained positive and in line with market expectations. The Company demonstrated ongoing progress with substantial growth in revenues, EBITDA, and order intake during the period. These successes have been achieved through a combination of contract wins in the UK and internationally, earnings accretive acquisitions and continual improvement in operational efficiencies.